Angiotech completes Neucoll merger:
This article was originally published in Clinica
Executive Summary
Angiotech Pharmaceuticals has completed its acquisition of Neucoll, a privately-held orthobiologics company based in Los Gatos, California. Vancouver, Canada-based Angiotech first announced its intention to acquire all the share capital of Neucoll in July (see Clinica No 1114, p 13) as part of its strategy to build up its orthopaedics business. With this $13m all-cash transaction, Angiotech has bought Neucoll's two key products, the Collagraft and Neugraft bone graft matrixes.